CD274 and lung carcinoma: In lung cancer, in pre-treatment plasma EVs from advanced NSCLC patients, high levels of miR-200c-3p, miR-21-5p, and miR-28-5p have been reported in non-responder patients to anti-PD1 or anti-PDL1 therapy.